<?xml version="1.0" encoding="UTF-8"?>
<p id="p0225">Recently, clustered regularly interspaced short palindromic repeats (CRISPR) based nucleic acid detection technology has emerged as a powerful tool with the advantages of rapidity, simplicity and a low cost (
 <xref rid="bb0635" ref-type="bibr">Wang et al., 2020</xref>). A recent study reported that the CRISPR-based assay was used to detect SARS-CoV-2 in the patient's pharyngeal swab in China (
 <xref rid="bb0005" ref-type="bibr">Ai et al., 2020</xref>). The turn-around time (TAT) of CRISPR was 2 h, much faster than RT–PCR (3 h) and mNGS (24 h) (
 <xref rid="bb0005" ref-type="bibr">Ai et al., 2020</xref>). The FDA authorized a COVID-19 test that uses the gene-editing technology CRISPR. Sherlock CRISPR SARS-CoV-2 Kit has been developed by Sherlock Biosciences Inc.
</p>
